Back to results
US 12,385,049 B2Granted
Modification of RNA, producing an increased transcript stability and translation efficiency
AssigneeBioNTech SE
InventorsUgur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
Life of this patent
Estimating the term…
Abstract
It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
Claims30
An immunogenic composition comprising:
- an mRNA molecule comprising, in a 5′ to 3′ orientation:
- (a) a 5′ cap,
- (b) a sequence that encodes an antigen and ends with a termination codon,
- (c) a 3′-untranslated region (3′-UTR) extending from the termination codon to a 3′-terminal poly(A) tail sequence consisting of 100 to 150 consecutive A nucleotides,
- wherein the 3′-terminal nucleotide of the mRNA molecule is an A nucleotide of the poly(A) tail sequence;
- wherein the 3′-UTR is heterologous with respect to the sequence that encodes the antigen.
3 more elements
An isolated mammalian cell comprising:
- an mRNA molecule comprising, in a 5′ to 3′ orientation:
- (a) a 5′ cap,
- (b) a sequence that encodes a peptide or a protein and ends with a termination codon,
- (c) a 3′-untranslated region (3′-UTR) extending from the termination codon to a 3′-terminal poly(A) tail sequence consisting of 100 to 150 consecutive A nucleotides,
- wherein the 3′-terminal nucleotide of the mRNA molecule is an A nucleotide of the poly(A) tail sequence;
- wherein the 3′-UTR is heterologous with respect to the sequence that encodes the peptide or the protein;
- and
- wherein stability and/or translation efficiency of the mRNA molecule is increased as compared to that of an mRNA molecule with a poly(A) tail sequence that is shorter than 100 consecutive A nucleotides.
5 more elements
An isolated antigen-presenting cell comprising:
- an mRNA molecule comprising, in a 5′ to 3′ orientation:
- (b) a sequence that encodes a peptide or a protein and ends with a termination codon,
- (c) a 3′-untranslated region (3′-UTR) extending from the termination codon to a 3′-terminal poly(A) tail sequence consisting of 100 to 150 consecutive A nucleotides,
- wherein the 3′-terminal nucleotide of the mRNA molecule is an A nucleotide of the poly(A) tail sequence;
- wherein the 3′-UTR is heterologous with respect to the sequence encoding the peptide or the protein.
2 more elements
A method for stimulating or expanding antigen-specific T cells, the method comprising steps of:
- (a) obtaining an mRNA molecule comprising, in a 5′ to 3′ orientation:
- (i) a 5′ cap,
- (ii) a sequence that encodes an antigen and ends with a termination codon,
- (iii) a 3′-untranslated region (3′-UTR) extending from the termination codon to a 3′-terminal poly(A) tail sequence consisting of 100 to 150 consecutive A nucleotides,
- wherein the 3′-terminal nucleotide of the mRNA molecule is an A nucleotide of the poly(A) tail sequence;
- wherein the 3′-UTR is heterologous with respect to the sequence that encodes the antigen;
- (b) delivering the mRNA molecule to antigen-presenting cells under conditions such that the encoded antigen is expressed in the antigen-presenting cells;
- and
- (c) exposing T cells to the antigen-presenting cells from (b) under conditions that stimulate or expand antigen-specific T cells, wherein the number of antigen-specific T cells is increased, as compared to that of an mRNA molecule having a poly(A) tail sequence of no more than 51 consecutive A nucleotides.
6 more elements
A method of producing in vitro an mRNA molecule suitable for use as a pharmaceutical, the method comprising steps of:
- (i) obtaining a nucleic acid molecule comprising (a) a first nucleic acid sequence which codes for a nucleotide sequence comprising 100 to 150 consecutive A nucleotides, (b) a second nucleic acid sequence which is transcribable into mRNA, wherein the first nucleic acid sequence is located at the 3′ end of the second nucleic acid sequence, and (c) a recognition sequence for a type IIS restriction endonuclease that is located 3′ of the first nucleic acid sequence such that the corresponding cleavage site for the type IIS restriction endonuclease is located within the first nucleic acid sequence;
- (ii) cleaving the first nucleic acid sequence of the nucleic acid molecule from step (i) with a type IIS restriction endonuclease;
- and
- (iii) transcribing in vitro the nucleic acid molecule obtained after step (ii) thereby forming a transcript which comprises the mRNA transcribed from the second nucleic acid sequence and a 3-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides, wherein the 3-terminal nucleotide of said transcript is an A nucleotide, and
- wherein the transcript formed from step (iii) is characterized in that upon delivery into a mammalian cell, the stability and/or translation efficiency of the transcript is increased, as compared to that of a transcript without the 3′-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides.
2 more elements
A method of increasing the stability of an in vitro-transcribed mRNA molecule, the method comprising steps of:
- (i) obtaining a nucleic acid molecule comprising (a) a first nucleic acid sequence which, when transcribed, codes for a nucleotide sequence comprising 100 to 150 consecutive A nucleotides, (b) a second nucleic acid sequence which is transcribable into mRNA, wherein the first nucleic acid sequence is located at the 3′ end of the second nucleic acid sequence, and (c) a recognition sequence for a type IIS restriction endonuclease, that is located 3′ of the first nucleic acid sequence, such that the corresponding cleavage site for the type IIS restriction endonuclease is located within the first nucleic acid sequence;
- (ii) cleaving the first nucleic acid sequence of the nucleic acid molecule from step (i) with a type IIS restriction endonuclease;
- and
- (iii) transcribing in vitro the nucleic acid molecule obtained after step (ii) thereby forming a transcript which comprises the mRNA transcribed from the second nucleic acid sequence and a 3-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides, wherein the 3-terminal nucleotide of said transcript is an A nucleotide, wherein stability of the transcript is greater than that of a transcript without a 3′-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides.
1 more element
A method of increasing the expression efficiency of an mRNA transcript, the method comprising steps of:
- (i) obtaining an mRNA transcript comprising a coding sequence that encodes a peptide or a protein and a 3-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides, wherein the 3-terminal nucleotide of the mRNA transcript is an A nucleotide;
- and
- (ii) delivering the mRNA transcript to cells under conditions such that the peptide or protein encoded by the coding sequence is expressed in the cells, wherein expression efficiency of the coding sequence and thereby amount of the peptide or protein encoded by the coding sequence is increased as compared to that of the coding sequence of an mRNA transcript without a 3′-terminal nucleotide sequence of 100 to 150 consecutive A nucleotides.
Dependencies are inferred from the claim text.